Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00601640 · ClinicalTrials.gov registry record · Phase 2
Eflornithine and/or Diclofenac in Treating Patients With Sun-Damaged Skin
A Phase 2 study of Other Benign Neoplasm of Skin, Unspecified, sponsored by University of Arizona.
- Completed
- Registry status
- Phase 2
- Development phase
- 184
- Enrollment target
- 3
- Study locations
NCT00601640 is a Phase 2 study of Other Benign Neoplasm of Skin, Unspecified that has completed, run by University of Arizona. The registered enrollment target is 184 participants. The trial reports 3 study locations across 1 state.
The verdict
NCT00601640, a Phase 2 study of Other Benign Neoplasm of Skin, Unspecified, has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 184 participants
- Enrollment target
- 3
- Study locations
Study Summary
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of eflornithine and diclofenac may stop cancer from growing in patients with sun-damaged skin. PURPOSE: This randomized phase II trial is studying the side effects and how well eflornithine works compared with diclofenac, given alone or together, in treating patients with sun-damaged skin.
Conditions Studied
Interventions
- DRUG Diclofenac Na gel
- DRUG Eflornithine HCL ointment
Study Locations (3)
Arizona
- Virginia G. Piper Cancer Center at Scottsdale Healthcare - Shea - Tucson
- Veterans Affairs Medical Center - Tucson - Tucson
- Arizona Cancer Center at University of Arizona Health Sciences Center - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2007-01 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00601640
The ClinicalTrials.gov registry entry for NCT00601640 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 184 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Other Benign Neoplasm of Skin, Unspecified appearing as the primary indexed condition, and to 2 interventions - of which Diclofenac Na gel is the first listed.
NCT00601640 reports 3 study locations spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT00601640 about?
NCT00601640 is a clinical study titled "Eflornithine and/or Diclofenac in Treating Patients With Sun-Damaged Skin". RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of eflornithine and diclofenac may stop cancer from growing in patients with sun-damaged skin. PURPOSE: This randomized phase II trial is studying the side effects and how well eflornithine works compared wi...
What is the current status of trial NCT00601640?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 184 participants. The study started on 2007-01. Estimated completion is 2014-12.
What conditions does trial NCT00601640 study?
This clinical trial studies the following conditions: Other Benign Neoplasm of Skin, Unspecified.
What interventions are being tested in trial NCT00601640?
The interventions under investigation include: Diclofenac Na gel (DRUG), Eflornithine HCL ointment (DRUG).
Who is sponsoring clinical trial NCT00601640?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00601640 being conducted?
This trial has 3 study locations across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.